Earthquake today: 5.7 magnitude tremors strike Tibet
Tibet, May 12 (ANI): An earthquake of magnitude 5.7 on the Richter Scale jolted Tibet on Monday, a statement by the National Center for Seismology (NCS) said.
As per the NCS, the earthquake occurred at a shallow depth of 10km, making it susceptible to aftershocks.
In a post on X, the NCS said, "EQ of M: 5.7, On: 12/05/2025 02:41:24 IST, Lat: 29.02 N, Long: 87.48 E, Depth: 10 Km, Location: Tibet."
Earlier on May 8, an earthquake of magnitude 3.7 jolted the region.
In a post on X, the NCS said, "EQ of M: 3.7, On: 08/05/2025 20:18:41 IST, Lat: 29.20 N, Long: 87.02 E, Depth: 10 Km, Location: Tibet."
Shallow earthquakes like these are more dangerous than deeper ones due to their greater energy release closer to the Earth's surface. This causes stronger ground shaking and increased damage to structures and casualties, compared to deeper earthquakes, which lose energy as they travel to the surface.
The Tibetan Plateau is known for its seismic activity due to tectonic plate collisions.
Tibet and Nepal lie on a major geological fault line where the Indian tectonic plate pushes up into the Eurasian plate, and earthquakes are a regular occurrence as a result. The region is seismically active, causing tectonic uplifts that can grow strong enough to change the heights of the Himalayas' peaks, Al Jazeera reported.
"Education about earthquakes and earthquake-resilient buildings combined with funding for retrofits and resilient structures can help protect people and buildings when strong earthquakes occur," Marianne Karplus, a seismologist and geophysicist, told Al Jazeera.
"The earth system is very complex, and we cannot predict earthquakes. However, we can conduct scientific studies to better understand what causes earthquakes in Tibet and to better understand the shaking and impacts resulting from earthquakes," Karplus, who is a professor of geological sciences at the University of Texas at El Paso, told Al Jazeera. (ANI)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Hyderabad cardiologist gets US patent for multi-functional cardiac occluder
File photo: Dr Nageswara Rao Koneti HYDERABAD: An innovative device that can fix various types of cardiac defects, designed by Hyderabad-based Dr Nageswara Rao Koneti, who heads the Cardiology Division at Rainbow Children's Heart Institute, has been granted a US patent. Called KONAR-MF Occluder, the multi-functional device can close septal defects in children and adults. It is a double umbrella disc device made of nitinol, a biocompatible nickel and titanium alloy, and is stretchable up to 15 mm. It can treat various conditions, including ventricular septal defects, coronary arteriovenous fistulas, and paravalvular leaks. The device has already been patented in India, Europe (European Commission), Euro-African countries, and South Korea. The multifunctional device not only fixes multiple types of cardiac lesions but also makes advanced cardiac care more affordable for patients in India, as it costs just Rs 50,000 in India compared to Rs 1.2 lakh in Pakistan and Rs 2.5–6 lakhs in other parts of Asia and Europe, said Dr Koneti. Terming this as a proud moment for Indian science, Dr Koneti said: "This US patent validates that innovations from India can meet global standards. It took us over six years to develop the device, and we applied for CE approval in 2018.' He said the US patent now paves the way for a US FDA (US Food and Drug Administration) approval for the device, which has already been implanted in about 10-15 patients in the US on compassionate grounds. "But we can also do clinical trials in the US if required," said Dr Koneti, who is a paediatric interventional cardiologist. He pointed out that the device has already demonstrated its safety and efficacy through over 20 peer-reviewed studies, and over 10,000 of these devices have already been implanted in patients in over 90 countries across Asia, Europe, Latin America, and Africa since the device got CE approval in 2018. The device is manufactured by LifeTech Scientific of China. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
India Today
2 hours ago
- India Today
Isro chief reviews prep ahead of Indian astronaut's launch to space
With just days remaining until the launch of the landmark Axiom Mission 4 (Ax-4), Indian Space Research Organisation (Isro) chief V Narayanan visited Axiom Space's Houston facilities.,Axiom Space will launch Indian astronaut Shubhanshu Shukla on 14-day mission to the Space Station on June visit by the Indian space agency chief focused on Axiom's manufacturing and technical capabilities, as both organisations prepare for India's return to human spaceflight after more than four decades. advertisement The Ax-4 mission, now scheduled for launch on June 10, 2025, will see Group Captain Shubhanshu Shukla become only the second Indian to travel to space, and the first to visit the International Space Station (ISS).Shukla, serving as mission pilot, will join commander Peggy Whitson (USA), and mission specialists Sawosz Uznaski-Winiewski (Poland) and Tibor Kapu (Hungary) for a 14-day scientific mission aboard the the Isro Chairman's tour, Axiom Space leadership reiterated their commitment to supporting Isro's space ambitions. Days away from our historic #Ax4 human spaceflight mission, the ISRO Chairman visited the full complement of Axiom Space facilities with a focus on our team's manufacturing and technical expertise. We are committed to supporting ISRO's space endeavors Ax-4 and beyond! Axiom Space (@Axiom_Space) June 4, 2025The Ax-4 mission will conduct around 60 scientific studies involving 31 countries, with Isro selecting seven microgravity experiments in fields such as agriculture, food science, and human efforts are expected to provide critical experience for India's upcoming Gaganyaan mission and future space station Isro Chairman's visit marks a significant milestone in India's growing role in global space exploration and signals a new era of public-private collaboration in advancing human spaceflight. Must Watch
Indian Express
3 hours ago
- Indian Express
A father-son legacy of Padma honors and pioneering scientific research
Written by Siddhi Patil, Dr Chetan Eknath Chitnis, a globally renowned Indian scientist, has dedicated his life to combating malaria, a persistent global health challenge claiming countless lives annually. His groundbreaking work in malaria vaccine development has earned him the prestigious Padma Shri this year, alongside awards like the Shanti Swarup Bhatnagar Award and the Infosys Prize. Remarkably, Dr. Chitnis shares a rare distinction with his father, Eknath Vasant Chitnis, a Padma Bhushan recipient (1985) and a founding member of the Indian Space Research Organisation (ISRO). This rare father-son duo's Padma honors reflect a deep family legacy of scientific excellence, with both making transformative contributions to their respective fields. Dr. Chitnis's journey in medical research is deeply rooted in his upbringing. His father, a distinguished space scientist and former director of ISRO's Space Application Centre, instilled a passion for dedicated work. 'My father taught me that true commitment means loving what you do, no matter the hours,' Dr. Chitnis recalls. While he initially pursued physics, inspired by his father's rigor, it was his mother, a biochemist focused on cancer research, who steered him toward biology. This pivot led him to lead the Malaria Parasite Biology and Vaccines Unit at Institut Pasteur in Paris, where he drives innovative vaccine research to curb malaria's devastating impact. Pune holds a special place in Dr. Chitnis's heart. Childhood summers spent at his grandparents' home in Deccan Gymkhana, exploring nearby hills with cousins, evoke memories of a serene, green Pune. His parents' decision to settle in the city post-retirement deepened his connection. Today, as Pune evolves into a bustling hub of innovation, Dr. Chitnis is eager to engage with its academic and research communities, blending personal nostalgia with professional aspirations. From IIT Bombay to UC Berkeley, the National Institutes of Health, and the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi, Dr. Chitnis's career spans continents. His work at ICGEB, supported by robust government backing, laid the foundation for his current efforts in Paris. A significant breakthrough came during the COVID-19 pandemic when delayed vaccine trials at Oxford revealed that a 14-month gap between doses reduced malaria parasite growth—an unexpected finding inspired by similar COVID-19 vaccine insights. This discovery, coupled with advancements in mRNA technology, fuels his cautious optimism for future malaria solutions. The Padma Shri holds deep significance for Dr. Chitnis. 'Being recognised by my homeland, even after a decade abroad, is humbling,' he says. He views the award as a tribute to his team's collective efforts and a call to continue serving society.
